Stock research
Boston Scientific Corporation (BSX) Stock Research
Boston Scientific makes minimally invasive medical devices for cardiology, urology, and other specialties.
Boston Scientific Corporation reported revenue of $20.1B for the fiscal year ended December 31, 2025. Source: Form 10-K filed February 17, 2026
SEC data as of
- Ticker
- BSX
- Exchange
- NYSE
- Sector
- Health
- Founded
- —
Reported SEC XBRL figures. Each metric’s period and original filing are listed below.
Delayed Cboe One market data via TradingView. It may differ from primary-exchange or consolidated quotes.
About Boston Scientific
- Exchange
- NYSE: BSX
- Sector
- Health Care
- SEC industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Fiscal year end
- December 31
BSX key financials
Reported figures from Boston Scientific Corporation's filings, pulled directly from SEC XBRL data rather than a third-party terminal. Each row links to the filing it came from.
| Metric | Value | Period | Source |
|---|---|---|---|
| Revenue | $20.1B | 2025-01-01 – 2025-12-31 | SEC filing |
| Operating cash flow | $4.5B | 2025-01-01 – 2025-12-31 | SEC filing |
| Diluted EPS | $1.94 | 2025-01-01 – 2025-12-31 | SEC filing |
| Shares outstanding | 1.48B | As of 2026-01-30 | SEC filing |
Values are as tagged by the issuer in XBRL. Revenue for banks and insurers is net of interest expense where that is the reported line. Fiscal years that do not follow the calendar are shown by their period-end date. No price, market cap, or valuation multiple is shown because Yield Theory does not republish unlicensed market data.
Diluted EPS is the earnings figure behind the price-to-earnings ratio; the P/E multiple compression calculator shows how a change in that multiple moves a share price. Shares outstanding multiplied by the share price gives market capitalization.
What investors should watch in BSX
Boston Scientific Corporation sits in Health Care. Pharmaceuticals, biotech, medical devices, and managed care — defensive demand paired with binary drug and regulatory catalysts. We have not yet written company-specific drivers for BSX; the forces that matter most for the sector are:
- ◆Drug approvals and clinical-trial readouts
- ◆Medicare and drug-pricing policy
- ◆Demographics and an aging population
- ◆GLP-1 and obesity-drug demand
BSX primary sources
- Latest annual report: Form 10-K filed February 17, 2026
- Latest quarterly report: Form 10-Q filed August 3, 2026
- All BSX filings on SEC EDGAR
How we source and review company pages: research methodology.
Congressional trading in BSX
| Politician | Trade date | Type | Owner | Amount | Source |
|---|---|---|---|---|---|
| Kevin Hern | 2026-09-09 | Sale | Joint | $50,001 - $100,000 | Filing #20035491 |
| Kevin Hern | 2026-09-04 | Sale | Joint | $50,001 - $100,000 | Filing #20035491 |
| Kevin Hern | 2026-09-03 | Sale | Dependent | $1,001 - $15,000 | Filing #20035491 |
| Kevin Hern | 2026-09-03 | Sale | Dependent | $1,001 - $15,000 | Filing #20035491 |
| Kevin Hern | 2026-09-03 | Sale | Dependent | $1,001 - $15,000 | Filing #20035491 |
| Kevin Hern | 2026-08-31 | Sale | Joint | $15,001 - $50,000 | Filing #20035491 |
| Gilbert Cisneros | 2026-08-18 | Purchase | Self | $1,001 - $15,000 | Filing #20035390 |
| Gilbert Cisneros | 2026-06-05 | Purchase | Self | $1,001 - $15,000 | Filing #20034906 |
| Gilbert Cisneros | 2026-06-05 | Sale | Self | $1,001 - $15,000 | Filing #20034906 |
| John Boozman | 2026-06-04 | Sale | Joint | $1,001 - $15,000 | Filing #c52854ed-a778-483a-883c-0ba2bba17877 |
All verified BSX congressional disclosures
Congressional disclosures are delayed, range-based records—not real-time signals or proof of motive. See the source-linked tracker for scope and limitations.
Compare BSX with similar companies
Boston Scientific peers
BSX — frequently asked questions
What does Boston Scientific Corporation do?
Boston Scientific makes minimally invasive medical devices for cardiology, urology, and other specialties.
What were BSX's latest reported annual revenue and net income?
Boston Scientific Corporation reported revenue of $20.1B for the fiscal year ended December 31, 2025. The figures come from Boston Scientific Corporation's SEC XBRL filings.
When does Boston Scientific Corporation's fiscal year end?
The SEC lists Boston Scientific Corporation's fiscal year end as December 31.
Do members of Congress trade BSX?
The current verified House and Senate snapshot contains 39 transaction rows for BSX, each linked to the original filing.
Is BSX a good investment?
This page does not rate BSX as a buy or sell. It sets out what Boston Scientific Corporation reports, what investors should watch and the questions a thesis has to answer, with links to the SEC filings. It is research, not investment advice.
This page is independent research and educational information, not investment advice or a recommendation to buy or sell any security. Company facts are compiled from public sources. Do your own research.
What do the BSX numbers leave unanswered?
Financials describe the business. The next question is which assumptions an investment thesis depends on. Explore the member reports below for analysis of catalysts, risks, and what would change the view. $39/month or $249/year.
Members-only research
$39/mo or $249/yr · cancel future renewals anytime · sources included